Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GME751 vs Keytruda in Untreated Metastatic Non-squamous NSCLC
NCT06159790Phase 3Completed
- Sponsor
- Sandoz
- Start
- Apr 2024
- Primary completion
- Mar 2026
- Modality
- Monoclonal Antibodies
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial of GME751 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Sandoz. Primary endpoint: Best Overall Response at 9 months. Started Apr 2024; status: completed.
02
Drugs
GME751
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06159790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06159790.